GENERIC STEP THERAPY PLANS (GSTP)

DRUG CLASS **SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)**

PGST SSB – Ref# 374-D: Pexeva

HPGST SSB – Ref# 409-D: Pexeva, Trintellix, Viibryd

TGST SSB – Ref# 384-D: Pexeva, Trintellix, Viibryd

Status: CVS Caremark Criteria
Type: Initial Step Therapy; Post Step Therapy Prior Authorization

INITIAL STEP THERAPY

If the patient has filled a prescription for at least a 30 day supply of at least one generic SSRI drug within the past 365 days under a prescription benefit administered by CVS/caremark, then the requested branded drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the system will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

COVERAGE CRITERIA

Branded SSRIs will be covered with post step therapy prior authorization when the following criteria are met:

- Patient has experienced an inadequate treatment response, intolerance, or contraindication to at least one generic SSRI drug.

RATIONALE

If the patient has filled a prescription for at least a 30 day supply of at least one generic SSRI drug within the past 365 days under a prescription benefit administered by CVS/caremark, then the requested branded drug will be paid under that prescription benefit.

If the patient does not meet the initial step therapy criteria, then prior authorization is required.

If the patient has a documented contraindication to or a potential drug interaction with a generic drug, then the requested brand drug will be covered. If the patient is intolerant to at least one of the generic drugs, then the requested brand drug will be covered. If the patient has tried one of the generic drugs for at least 30 days and had an inadequate treatment response, then the requested brand drug will be covered. If these requirements are met, then the approval duration is 24 months.

REFERENCES

N/A

Written by:	UM Development
Date Written:	04/2009
Revised:	10/2009, 09/2010, 05/2011, 06/2011, 12/2011, 09/2012 (updated formatting and documentation), 10/2012 (removed documentation), 03/2013 (removed Viibryd from PGST, updated grids), 03/2013 (removed Luvox CR), 09/2013 (re-worded question 2), 01/2014 (added Brintellix), 09/2014 (reordered questions), 09/2015, 05/2016 (changed Brintellix to Trintellix due to name change), 09/2016 (removed Trintellix from PGST) , (SF) 09/2017 (no changes)
Reviewed:	Medical Affairs 05/2009, 10/2009, 09/2010, 06/2011, 12/2011, (LS) 09/2012, 03/2013, (DC) 09/2013, (KP) 01/2014, (SS) 09/2014, (MM) 09/2015
External Review:	05/2009, 12/2009, 12/2010, 12/2011, 02/2013, 12/2013, 02/2014, 12/2014, 12/2015, 12/2016, 12/2017

CRITERIA FOR APPROVAL

© 2017 Caremark. All rights reserved. This document contains confidential, privileged and proprietary information of CVS/caremark. It cannot be reproduced, distributed or printed without written permission from CVS/caremark. Clinical criteria may change at any time based on at-risk generic launches, new drug approvals, formulary changes and other market and regulatory events. Updates to the clinical criteria and GSTP may be made quarterly. This page contains prescription brand name drugs that are registered or trademarks of pharmaceutical manufacturers that are not affiliated with CVS/caremark Inc.

1	Has the patient demonstrated an inadequate treatment response after at least a 30 day trial of at least one generic SSRI? [If yes, then no further questions.]	Yes	No
2	Does the patient have a documented contraindication to or a potential drug interaction with at least one generic SSRI? [If yes, then no further questions.]	Yes	No
3	Has the patient had a trial and was intolerant to at least one generic SSRI?	Yes	No

Guidelines for Approval					
Duration of Approval		**24 Months**			
Set 1 – Failed Trial		**Set 2 – Contraindication**		**Set 3 – Intolerant**	
Yes to question(s)	**No to question(s)**	**Yes to question(s)**	**No to question(s)**	**Yes to question(s)**	**No to question(s)**
1	None	2	1	3	1
					2

Mapping Instructions		
	Yes	**No**
1.	Approve for 24 months	Go to 2
2.	Approve for 24 months	Go to 3
3.	Approve for 24 months	Deny

© 2017 Caremark. All rights reserved. This document contains confidential, privileged and proprietary information of CVS/caremark. It cannot be reproduced, distributed or printed without written permission from CVS/caremark. Clinical criteria may change at any time based on at-risk generic launches, new drug approvals, formulary changes and other market and regulatory events. Updates to the clinical criteria and GSTP may be made quarterly. This page contains prescription brand name drugs that are registered or trademarks of pharmaceutical manufacturers that are not affiliated with CVS/caremark Inc.